H.R.2315 - Preserving Access to Orphan Drugs Act of 2013113th Congress (2013-2014)
|Sponsor:||Rep. Gerlach, Jim [R-PA-6] (Introduced 06/11/2013)|
|Committees:||House - Energy and Commerce; Ways and Means|
|Latest Action:||House - 07/25/2013 Rereferred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.2315 — 113th Congress (2013-2014)All Information (Except Text)
Introduced in House (06/11/2013)
Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million.
Makes this Act effective as if included in PPACA.